Loading...
XSHE002424
Market cap707mUSD
Jan 10, Last price  
3.63CNY
1D
-1.63%
1Q
7.08%
Jan 2017
-79.98%
IPO
-1.20%
Name

Guizhou Bailing Group Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002424 chart
P/E
—
P/S
1.22
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.88%
Rev. gr., 5y
6.33%
Revenues
4.26b
+20.42%
446,203,927607,359,234734,517,818863,756,4491,138,426,6791,367,582,4471,405,330,3311,574,672,1621,899,087,6192,214,211,0742,591,816,6503,136,843,2312,850,585,2503,087,888,2013,111,649,5473,540,132,2724,262,971,440
Net income
-415m
L
71,905,04780,295,567111,666,857158,198,365208,381,046221,752,172269,604,476310,477,902411,374,642482,327,097526,137,360563,238,885282,748,962152,375,357118,482,584138,473,917-414,511,221
CFO
126m
-74.95%
00125,307,7330201,903,32219,516,226141,756,275395,833,192413,228,742466,615,47979,884,2490467,413,827231,779,655324,922,220502,152,213125,767,058
Dividend
May 29, 20200.22 CNY/sh
Earnings
May 20, 2025

Profile

Guizhou Bailing Group Pharmaceutical Co., Ltd. researches, develops, produces, and sells Chinese medicines in China. The company provides medicines in the form of tablets, capsules, granules, syrups, pills, powders, tinctures, sprays, and ointments for cardiovascular and cerebrovascular diseases, cough, cold, pediatric, and gynecologic diseases. Guizhou Bailing Group Pharmaceutical Co., Ltd. was founded in 2005 and is based in Anshun, China.
URL
https://www.gzbl.com/
IPO date
Jun 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,262,971
20.42%
3,540,132
13.77%
Cost of revenue
3,984,261
3,043,500
Unusual Expense (Income)
NOPBT
278,710
496,632
NOPBT Margin
6.54%
14.03%
Operating Taxes
(80,605)
23,086
Tax Rate
4.65%
NOPAT
359,316
473,546
Net income
(414,511)
-399.34%
138,474
16.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
(100,006)
BB yield
0.89%
Debt
Debt current
1,318,299
1,526,299
Long-term debt
278,693
94,558
Deferred revenue
34,957
22,385
Other long-term liabilities
27,254
Net debt
(262,560)
(456,585)
Cash flow
Cash from operating activities
125,767
502,152
CAPEX
(104,118)
Cash from investing activities
(34,831)
20,439
Cash from financing activities
(215,239)
FCF
634,479
793,693
Balance
Cash
417,939
605,023
Long term investments
1,441,614
1,472,419
Excess cash
1,646,404
1,900,435
Stockholders' equity
3,184,767
3,961,184
Invested Capital
3,591,554
3,603,131
ROIC
9.99%
12.73%
ROCE
5.29%
8.97%
EV
Common stock shares outstanding
1,381,704
1,397,598
Price
8.11
-0.61%
8.16
7.37%
Market cap
11,205,620
-1.74%
11,404,403
7.37%
EV
10,957,952
10,950,087
EBITDA
402,952
612,796
EV/EBITDA
27.19
17.87
Interest
86,848
101,656
Interest/NOPBT
31.16%
20.47%